NASDAQ:SYRS - Syros Pharmaceuticals Stock Price, Forecast & News

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Syros Pharmaceuticals Inc (NASDAQ:SYRS) announced its earnings results on Tuesday, November, 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.48) by $0.01. The firm had revenue of $0.56 million for the quarter, compared to analyst estimates of $0.43 million. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 84.49%. View Syros Pharmaceuticals' Earnings History.

Syros Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Syros Pharmaceuticals.

7 analysts have issued 12 month price targets for Syros Pharmaceuticals' stock. Their forecasts range from $9.00 to $18.00. On average, they expect Syros Pharmaceuticals' stock price to reach $13.83 in the next twelve months. This suggests a possible upside of 90.5% from the stock's current price. View Analyst Price Targets for Syros Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syros Pharmaceuticals.

Media headlines about SYRS stock have been trending somewhat negative this week, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Syros Pharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Syros Pharmaceuticals.

Syros Pharmaceuticals saw a increase in short interest in January. As of January 15th, there was short interest totalling 2,340,000 shares, an increase of 30.0% from the December 31st total of 1,800,000 shares. Based on an average daily trading volume, of 479,200 shares, the days-to-cover ratio is presently 4.9 days. Approximately 7.6% of the shares of the company are short sold. View Syros Pharmaceuticals' Current Options Chain.

Some companies that are related to Syros Pharmaceuticals include IGM Biosciences (IGMS), Madrigal Pharmaceuticals (MDGL), ZEALAND PHARMA/S (ZEAL), Myovant Sciences (MYOV), Athenex (ATNX), Endonovo Therapeutics (ENDV), Rocket Pharmaceuticals (RCKT), Enanta Pharmaceuticals (ENTA), Portola Pharmaceuticals (PTLA), Opko Health (OPK), Karyopharm Therapeutics (KPTI), Phibro Animal Health (PAHC), Dermira (DERM), NextCure (NXTC) and Revance Therapeutics (RVNC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Zynerba Pharmaceuticals (ZYNE), Nektar Therapeutics (NKTR), Sangamo Therapeutics (SGMO), Synergy Pharmaceuticals (SGYP), TherapeuticsMD (TXMD), Global Blood Therapeutics (GBT), Galmed Pharmaceuticals (GLMD), ImmunoGen (IMGN) and Viking Therapeutics (VKTX).

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Syros Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include California Public Employees Retirement System (0.07%). Company insiders that own Syros Pharmaceuticals stock include Jeremy P Springhorn, Richard A Young, Srinivas Akkaraju and Venture Fund Vii LP Arch. View Institutional Ownership Trends for Syros Pharmaceuticals.

SYRS stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System. Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn and Srinivas Akkaraju. View Insider Buying and Selling for Syros Pharmaceuticals.

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SYRS stock can currently be purchased for approximately $7.26.

Syros Pharmaceuticals has a market capitalization of $308.12 million and generates $2.05 million in revenue each year. The company earns $-62,280,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe.View Additional Information About Syros Pharmaceuticals.

The official website for Syros Pharmaceuticals is http://www.syros.com/.

Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]